OTICON-MEDICAL
Oticon Medical announced today the U.S. Food and Drug Administration (FDA) clearance of its first active transcutaneous bone conduction hearing system, the Sentio System. Sentio System delivers the proven benefits of the Ponto™ System – and more – in a transcutaneous option.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240712765107/en/
The Sentio System includes an external Sentio 1 Mini sound processor and a Sentio Ti Implant placed under the skin. (Photo: Business Wire)
The system includes Sentio 1 Mini, an external sound processor, and Sentio Ti Implant, placed under the skin. It is the smallest transcutaneous system available to date1.
While Ponto and other percutaneous bone-anchored hearing systems use skin-protruding abutments, the Sentio System provides an alternative keeping the skin intact. The Sentio System offers an additional solution for patients and supports our commitment to "freedom of choice."
“With the launch of Sentio System, we provide best-in-class and the smallest active transcutaneous system. More importantly, Oticon Medical now offers a complete portfolio of bone-anchored hearing systems. This portfolio meets the needs of patients and customers, and fits diverse clinical settings and global reimbursement schemes for the treatment. We strongly believe that offering a broad portfolio is the path to achieving our mission to "Help more people" and give more potential users the quality of life improvements these systems offer”, says René Govaerts, President & General Manager, Oticon Medical.
The Sentio 1 Mini is designed with a focus on user comfort and ease of use. The device's design and slim profile make it 26% lighter than an alternative1. It gives access to a 360-degree sound experience and offers the widest bandwidth of 9.5kHz.
Sentio Ti is a SuperPowerful implant developed to support patient’s progressive hearing loss, without the need for additional surgeries. Sentio Ti is designed and verified for a higher maximum force output, so that patients can rely on its ability to handle more powerful sound processors2. From a surgeon’s perspective, the implant is designed for surgical flexibility, ensuring a straightforward procedure.
Sentio System is indicated for candidates aged 12 and older who have been diagnosed with conductive hearing loss, mixed hearing loss, or single-sided deafness.
This launch marks a significant milestone for Oticon Medical, as it continues to deliver the innovative hearing solutions that help people live life to the fullest.
For more information visit www.oticonmedical.com.
Not all products are available in all markets. Product availability and indications are subject to regulatory approval and may vary depending on the market.
About Oticon Medical
Oticon Medical is a global company in implantable hearing solutions, dedicated to bringing the power of sound to people at every stage of life. For more than a decade, we have made bone anchored hearing systems more accessible by simplifying the treatment for physicians, audiologists, and patients alike.
We believe that patients and hearing care professionals should be able to choose the best possible solution at any time along the patient journey. We call it “Freedom of Choice” and it has always been paramount to Oticon Medical. This is the reason why our solutions are designed to be compatible whenever possible. As a result, an implant from Oticon Medical stands as a true testament to our unwavering lifelong support.
We work collaboratively with professionals to ensure that every solution we create is designed with our users’ needs in mind. We have a strong passion to provide innovative solutions and support that enhance quality of life and help people live life to the fullest – now and in the future.
Because we know how much sound matters.
References
1 Sentio implant and sound processor physical features and comparison to other devices (Doc-00123204)
2 275144en Product Information Sentio 1 Mini
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240712765107/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LTIMindtree Launches ‘BlueVerse’ — An AI Ecosystem that will Define the Enterprise of the Future19.6.2025 11:30:00 CEST | Press release
LTIMindtree [NSE: LTIM, BSE: 540005], a global technology consulting and digital solutions company, has announced the launch of a new business unit and suite of AI services and solutions: BlueVerse. Designed as a complete AI ecosystem, it helps enterprises accelerate their AI concept-to-value journey. This ecosystem is a universe of components that enterprises need to elevate business operations, achieve breakthrough productivity, and create transformational customer experiences. BlueVerse Marketplace currently has over 300 industry and function-specific agents and ensures seamless interoperability and a growing connector ecosystem. It is underpinned by responsible AI governance, delivering enterprise-grade trust and scalability. BlueVerse Productized Services utilize repeatable frameworks, accelerators, and industry-specific solution kits. At launch, BlueVerse will offer pre-built solutions for Marketing Services and Contact Center as a Service (CCaaS). With Marketing Services busines
KIKO Milano Partners with Logistics Reply to Accelerate E-Commerce Delivery in the UK Market19.6.2025 10:00:00 CEST | Press release
Logistics Reply, the Reply group company specialising in innovative supply chain solutions has partnered with KIKO Milano, the global cosmetics brand renowned for its cutting edge, high-quality beauty products, to transform its e-commerce operations in the UK. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250619841029/en/ This partnership represents a strategic milestone in KIKO’s broader digital transformation journey and reinforces its commitment to operational excellence and an exceptional customer experience. With rapid growth in the UK market and a rising demand for online shopping and fast home delivery, KIKO recognized the need to evolve its supply chain operations. To meet these challenges, KIKO opened a new dark store in London and selected Logistics Reply with its LEA Reply™ Warehouse Management System (WMS) to build a more scalable and agile logistics infrastructure. A dark store is a retail distribution centre t
Chiesi Global Rare Diseases Awards Research Grants to Advance Innovation in Lysosomal Diseases19.6.2025 09:35:00 CEST | Press release
Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative solutions for people living with rare diseases, today announced the recipients of its "Find For Rare" research grant program. The independently assessed, expert-led research grant initiative aims to improve patient care and management by recognising innovative research in three lysosomal diseases: Fabry disease, alpha-mannosidosis, and cystinosis. The selected projects demonstrated significant potential to address unmet needs within these rare communities. The recipients include: Fabry disease: Mitra Tavakoli, University of Exeter, Exeter, UK, for her project "FAB-PAIN: Precise phenotyping of neuropathy using a range of novel biomarkers in Fabry Disease” Project overview: This project aims to explore a range of novel biomarkers to better understand the pain pathways and its pathophysiology in Fabry disease. The findings may lead to the development of a range of new neuropathic biomarkers,
Brenus Pharma and InSphero Have Developed 3D Tumor Spheroids Mimicking in vivo Human Colorectal Cancer Conditions and Confirming STC-1010’s Efficacy19.6.2025 09:15:00 CEST | Press release
Presented at EACR 2025, promising results show the impact of Brenus Pharma and InSphero’s collaboration in advancing translational immunotherapy through scalable 3D tumor models. Brenus Pharma, a French biotech developing next-generation first-in-class immunotherapies, and InSphero, a Swiss leader in 3D cell-based assay technologies, presented promising data at the European Association for Cancer Research 2025 annual congress. These data confirm the use of 3D tumor spheroids for potency testing of STC-1010, Brenus’ lead candidate for colorectal cancer. Funded through the EUROSTARS program, the collaboration led to vitrified 3D colorectal cancer spheroids using tumor cell lines co-cultured with fibroblasts. The vitrification method preserves morphology, stromal integrity, and viability after thawing, enabling realistic evaluation of STC-1010’s therapeutic potential under conditions mimicking in vivo human tumors. Previous studies showed that STC-1010 antigens were effectively processed
Textron Aviation Defense and Thai Aviation Industries Sign Agreement to Support Royal Thai Air Force19.6.2025 08:30:00 CEST | Press release
During the Paris Air Show, Textron Aviation Defense LLC., a Textron Inc. (NYSE: TXT) company, and Thai Aviation Industries Co., Ltd. signed a Memorandum of Agreement to work together on a sustainment program for the Royal Thai Air Force (RTAF). This program will support RTAF's fleets of Beechcraft T-6TH and AT-6TH aircraft. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250618711147/en/ Textron Aviation Defense LLC. and Thai Aviation Industries Co., Ltd. sign a Memorandum of Agreement to sustain Beechcraft T-6TH trainer and AT-6TH light attack aircraft for the Royal Thai Air Force (RTAF) The Beechcraft T-6TH trainer and AT-6TH light attack aircraft are designed and manufactured by Textron Aviation Defense LLC., a wholly owned subsidiary of Textron Aviation Inc. Textron Aviation Defense, based in Wichita, Kansas, USA, is the original equipment manufacturer (OEM) for these aircraft. Thai Aviation Industries, located in Bangkok
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom